Combining Stellate Ganglion Block With Prolonged Exposure for PTSD

Status Recruiting

Clinical Trial Summary

The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of military service members or retirees with PTSD. The main questions it aims to answer are: (1) Does the addition of an SGB improve treatment outcomes associated with Massed PE and (2) Do differences in psychophysiological arousal during the exposure portion of treatment help explain treatment outcomes for PTSD. Participants will receive ten 90-minute session of Massed PE. Between the first and second Massed PE sessions, half of the participants will receive a SGB, and half will receive a sham SGB.

Clinical Trial Description

Massed PE will be conducted by master-level or doctoral-level therapists. Participants will meet with their providers for individual, 90-minute sessions. They will then be asked to complete out-of-session treatment assignments throughout the rest of the day. Between the individual therapy session and out-of-session treatment assignments, participants will engage in approximately four to six hours of treatment per day, Monday through Friday, for two weeks. Each participant will also be offered three booster sessions at 1-, 3-, and 7-weeks posttreatment. The stellate ganglion block injection or the sham SGB will be administered between the first and second massed PE session by qualified medical personnel as per standard operating procedure for the placement of a stellate ganglion block. A research nurse will be in attendance during the procedure and for an hour recovery period following the block administration. Assessments will be administered at pretreatment, during treatment, at posttreatment, and at 1-, 3-, and 6-months following the completion of PE. The primary outcome assessment will be 1-month following the completion of PE. Following this assessment, participants randomized to the sham SGB arm of the study will be offered an SGB with ropivacaine. ;

Study Design

Related Conditions & MeSH terms

Stress Disorders, Post-Traumatic

Clinical Trial Details

NCT number	NCT05889741
Study type	Interventional
Source	The University of Texas Health Science Center at San Antonio
Contact	Amanda Flores
Phone	210-562-6726
Email	floresa13@uthscsa.edu
Status	Recruiting
Phase	Phase 2
Start date	February 26, 2024
Completion date	August 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05620381` - Health and Sleep Assessment After the Strasbourg Attacks of December 11, 2018
Completed	`NCT02856412` - Improving Mind/Body Health and Functioning With Integrative Exercise	N/A
Recruiting	`NCT05400200` - PTSD and Self-regulation: Coping, Emotional Regulation and Cognitive Control and Their Relationships to Symptom Management	N/A
Not yet recruiting	`NCT06088303` - Enhancing PTSD Treatment Outcomes by Improving Patient-Provider Communication	N/A
Not yet recruiting	`NCT03652922` - Propranolol Reactivation Mismatch (PRM) Treatment for PTSD	Phase 4
Completed	`NCT02875912` - Prospective Evaluation of Family Care Rituals in the ICU	N/A
Completed	`NCT01589575` - Anxiety and Depression in Relatives of Critically Ill Patients: Spouses Versus Other Close Relatives	N/A
Completed	`NCT01291368` - Sedation Influence on Delirium and Post-traumatic Stress-disorder as a Result of Hospitalization in Intensive Care	N/A
Completed	`NCT00990106` - Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)	N/A
Active, not recruiting	`NCT00657787` - Development of a Post-Traumatic Stress Disorder (PTSD) Population Registry for Veterans
Completed	`NCT00880152` - Mindfulness Based Stress Reduction for Posttraumatic Stress Disorder: A Pilot Study	N/A
Completed	`NCT01365247` - Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD)	N/A
Completed	`NCT00835627` - Treatment Trial for Psychogenic Nonepileptic Seizures	Phase 4
Completed	`NCT00514956` - Effect of Emotional Freedom Technique and Diaphragmatic Breathing on Post Traumatic Stress Disorder (PTSD)	Phase 1
Completed	`NCT00419029` - Motivational Interviewing to Engage Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans in Mental Health Treatment	N/A
Completed	`NCT00333710` - Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD	N/A
Completed	`NCT01120847` - Post Traumatic Stress Disorder (PTSD), Sleep Disordered Breathing And Genetics: Effects On Cognition
Completed	`NCT00069225` - Brain Structure and Function Before and After Treatment for Post-Traumatic Stress Disorder	N/A
Completed	`NCT00055354` - Acupuncture for the Treatment of Post-Traumatic Stress Disorder (PTSD)	N/A
Completed	`NCT00186212` - Alternative Support for Rural and Isolated Women in an HMO	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.